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We report Salmonella enterica serotype Typhi strains with a nonclassical quinolone resistance phenotype 
(i.e., decreased susceptibility to ciprofloxacin but with susceptibility to nalidixic acid) associated with a 
nonsynonymous mutation at codon 464 of the gyrB gene. These strains, not detected by the nalidixic acid 
disk screening test, can result in fluoroquinolone treatment failure.   
Typhoid fever caused by Salmonella enterica serotype Typhi (hereafter referred to as 
Salmonella Typhi) remains a major health problem in the developing world (1). Treatment with 
appropriate antimicrobial drugs has become hampered by gradual plasmid-mediated resistance to 
ampicillin, chloramphenicol, and cotrimoxazole, particularly in South and Southeast Asia (2). 
Consequently, since the early 1990s, fluoroquinolones (such as ofloxacin and ciprofloxacin 
[Cip]) have been widely used. However, multidrug-resistant Salmonella Typhi isolates that are 
also resistant to nalidixic acid (Nal
R) (MIC >256 μg/mL) and show decreased susceptibility to 
Cip (Cip
DS) (MIC range, 0.125 μg/mL–1 μg/mL) have emerged and become endemic on the 
Indian subcontinent and in Southeast Asia (3–5). This resistance to quinolones was caused by 
amino acid substitutions in the quinolone resistance–determining region (QRDR) of the DNA 
gyrase subunit gyrA, a key target of quinolones. Because these Nal
R–Cip
DS Salmonella Typhi Page 2 of 8 
strains have been associated with slower clinical responses to fluoroquinolones and treatment 
failures, clinical laboratories should attempt to identify these isolates (3,6,7). However, despite 
the accumulation of clinical, microbiologic, and pharmacokietic–pharmacodynamic studies 
suggesting a resistance breakpoint of >0.125 μg/mL for ciprofloxacin, the clinical breakpoints 
published by the Clinical and Laboratory Standards Institute (CLSI) (susceptibility <1 μg/mL, 
resistance >4 μg/mL) and those from the antibiogram committee of the French Society for 
Microbiology (CA-SFM) (susceptibility  <0.5 μg/mL, resistance  >1 μg/mL) 
(www.sfm.asso.fr/nouv/general.php?pa=2) have not been reevaluated (6–9). Use of these 
standard breakpoints has probably resulted in the underreporting of Cip
DS Salmonella Typhi 
strains. The Nal
R screening test has been proposed as an alternative since the mid–1990s and 
recommended since 2004 by CLSI and 2010 by CA-SFM (3,7). This screening test is based on 
the fact that Cip
DS Salmonella Typhi isolates with nonsynonymous (NS) mutations in codons 83 
or 87 of gyrA are uniformly Nal
R. However, recent reports have indicated that this approach 
cannot identify the newly described Salmonella Typhi isolates that are Nal susceptible (Nal
S)–
Cip
DS for which mechanisms of resistance are not linked to mutations in gyrA (7,10,11). 
Recently, NS mutations in codons 464 (Ser to Phe) and 466 (Glu to Asp) of gyrB were found in 7 
Nal
S–Cip
DS Salmonella Typhi isolates (12). We present data on the occurrence and 
characterization of the resistance mechanisms of Nal
S–Cip
DS isolates in 685 Salmonella Typhi 
isolates of the French National Reference Center for Salmonella (FNRC-Salm). 
The Study 
In France, laboratory surveillance of typhoid fever infections is performed by the FNRC-
Salm through its network of ≈1,500 hospital and private clinical laboratories. Almost all 
Salmonella Typhi isolates in France are referred to the FNRC-Salm, and almost all are acquired 
abroad, mainly in Africa and Asia. Until 2009, Cip
DS Salmonella Typhi was monitored with the 
30-μg Nal screening test. A total of 685 Salmonella Typhi isolates collected during 1997–2009 
were reanalyzed to identify Nal
S–Cip
DS Salmonella Typhi isolates. The scattergram correlating 
the zone diameters around the 5-μg ciprofloxacin disk with those of the 30-μg Nal disk showed 4 
subpopulations, which were labeled A (554 isolates), B (11 isolates), C (119 isolates), and D (1 
isolate) (Figure 1). The characteristics of these populations are shown in Tables 1 and 2. The 
QRDRs of gyrA, gyrB, parC, and parE genes were studied on 133 isolates selected to represent Page 3 of 8 
diversity in terms of year of isolation, geographic origin, and MICs. To analyze the isolate 
characteristics, we used the following approaches: sequencing (5), denaturing high performance 
liquid chromatography (4), and Luminex-based genotyping assays (12). QRDR DNA sequences 
were compared with those of Salmonella Typhi strain Ty2 (GenBank accession no. AE014613). 
In subpopulation A, 75 isolates had wild-type QRDR sequences, whereas 2 isolates had a gyrB 
mutation at codon 465 leading to amino acid substitution Gln to Leu. Their Nal MICs were 2 and 
4 μg/mL, respectively, and those of Cip were 0.04 μg/mL and 0.08 μg/mL, respectively. Notably, 
both isolates were acquired in Mexico during 1998 and 2009, respectively. In subpopulation C, 
the lowest MIC values for Cip (0.06 μg/mL) were associated with a mutation at codon 87 of the 
gyrA gene, whereas MICs did not increase with the additional mutation in the parE gene. 
Subpopulation D consisted of 1 isolate, highly resistant to ciprofloxacin, which was acquired by 
a traveler in India in 2004. This isolate contained 2 NS mutations in the gyrA gene and 1 in the 
parC gene. 
Eleven isolates of subpopulation B were categorized as susceptible to Nal by determining 
MICs and by using CLSI breakpoints (susceptibility, <16 μg/mL; resistance, >32 μg/mL). Of the 
11 isolates, 8 (from 7 patients) had a ciprofloxacin MIC >0.125 μg/mL and were thus classified 
as Cip
DS isolates. We were able to review the medical records of 2 patients infected with a Nal
S–
Cip
DS isolate. One patient (isolates 08-7675 and 09-1986) relapsed 15 days after completion of 
the treatment (oral ofloxacin, 200 mg 2×/d for 8 days) (13). The second patient (isolate 05-2556) 
was treated with extended-spectrum cephalosporins, and no fluoroquinolones. Regarding the 
resistance mechanisms the plasmid-mediated quinolone resistance–conferring genes qnr (qnrA, 
B, S, D), qepA, and aac(6′)-Ib-cr were not detected by PCR (5,14). The QRDRs of gyrA, parC, 
and parE genes were of a wild type, whereas an NS mutation was found in gyrB for all but 1 
isolate. However, only the 8 isolates with mutations at codon 464 were Nal
S–Cip
DS. To assess 
whether these isolates were genetically related, haplotyping (4) and XbaI-pulsed-field gel 
electrophoresis (PFGE) subtyping (5) were performed. On the strength of the results, we 
concluded that the gyrB mutation was acquired independently by strains belonging to different 
PFGE types (Figure 2). According to a newly developed single nucleotide polymorphism assay 
(Y.S.), 2 of these strains belong to the current emerging H58 Asian population (4), whereas the 
others do not (Table 2). In our study, the Nal
S–Cip
DS isolates with gyrB mutations at codon 464 
were most often non–multidrug-resistant and acquired mainly in India. Our first Nal
S–Cip
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isolate was isolated 13 years ago, and since is rare (prevalence ≈1%.). Although Cooke et al. (10) 
did not characterize isolates for their resistance mechanisms, they reported that Nal
S–Cip
DS 
represented 11.6% (49/421) of Salmonella Typhi isolated in England, Scotland, and Wales 
during 1999–2003, while Lynch et al. (11) reported that such isolates were 4.6% (36/770) of 
Salmonella Typhi isolates identified in the United States during 1999–2006. Epidemiologic data 
were available for 39 isolates in the British study, 18 of which were acquired in India, 8 in 
Pakistan, and 4 in Bangladesh (10). The 10-fold difference in the prevalence observed between 
our study and that of Cooke et al. are probably related to the historical links and the subsequent 
population flow between the United Kingdom and the Indian subcontinent. 
Conclusions 
Nal
S–Cip
DS Salmonella Typhi isolates originating from Asia comprise ≈1% of 
Salmonella Typhi isolates in France but are more prevalent in the United States and the United 
Kingdom. The NS gyrB mutation at codon 464 was found exclusively in Nal
S–Cip
DS isolates; 
however, the effects of this mutation need to be formally demonstrated by site-directed 
mutagenesis. Furthermore, the involvement of an efflux system, such as AcrAB-TolC and OqxA, 
or the qnrC gene, have not been investigated and cannot be excluded. 
Whatever the molecular mechanism of resistance of such strains, the main concern is 
detection of such isolates in clinical practice to prevent fluoroquinolone treatment failures. 
Consequently, the Nal
R screening test should no longer be recommended and ciprofloxacin drug 
MICs should be determined for all Salmonella Typhi isolates instead. There is also a clear need 
to reevaluate the clinical breakpoints for this pathogen.    
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Table 1. Characteristics of the 674 Salmonella enterica serovar Typhi isolates belonging to subpopulations A, C, and D, France, 2007–
2009* 
Subpopulation 
No. 
isolates 
Nal MICs,† μg/mL 
 
Cip MICs,† μg/mL 
QRDR mutation (no./no. tested)  MIC50  MIC90  Range  MIC50  MIC90  Range 
A  554  4  4  1–8    0.008  0.025  0.002–0.08  WT (75/77) 
                  gyrB Leu465 (2/77) 
C  119  >256  >256  128–>256    0.25  0.5  0.06–0.5  gyrA Phe83 (24/44) 
                  gyrA Tyr83 (12/44) 
                  gyrA Asn87 (4/44) 
                  gyrA Gly87 (2/44) 
                  gyrA Phe83 and parE Asn420 (2/44) 
D  1      >256        8  gyrA Phe83, gyrA Asn87, and parC Ile80 
*Nal, nalidixic acid; Cip, ciprofloxacin ; WT, wild type; QRDR, quinolone resistance–determining region of the gyrA, gyrB, parC, and parE genes.  
†MICs of Nal and Cip were determined by Etest strips. MIC50, 50% below; MIC90, 90% below. 
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Table 2. Characteristics of the 11 Salmonella enterica serovar Typhi isolates belonging to subpopulation B, France, 2007–2009 
Isolate  Year 
Geographic 
origin 
Antimicrobial drug 
resistance type 
Disk diffusion, mm 
 
MIC, μg/mL 
gyrB  Haplotype  PFGE  Nal  Cip  Nal  Cip 
97-5123  1997  Unknown  Cip
DS  18 [I]  28 [S]    8 [S/S]  0.125 [S/S]  Tyr464  Non-H58  X8 
02-2759  2002  India  Cip
DS  19 [I]  26 [S]    4 [S/S]  0.125 [S/S]  Phe464  H58  X2 
05-1578  2005  India  Pans susceptible  18 [I]  28 [S]    8 [S/S]  0.047 [S/S]  Asp466  Non-H58  X6 
05-2556  2005  India  Cip
DS  17 [I]  31 [S]    16 [I/S]  0.19 [S/S]  Phe464  Non-H58  X7 
05-9141  2005  India  Cip
DS  17 [I]  28 [S]    12 [I/S]  0.125 [S/S]  Tyr464  Non-H58  X3 
06-426  2006  India  Cip
DS  20 [S]  25 [S]    8 [S/S]  0.125 [S/S]  Tyr464  Non-H58  X3 
07-6086  2007  Tunisia  Pan susceptible  16 [I]  31 [S]    16 [I/S]  0.047 [S/S]  WT  ND  ND 
08-7675†  2008  India  ASCSulTmpSXTCip
DS  18 [I]  28 [S]    8 [S/S]  0.125 [S/S]  Phe464  H58  X1 
09-1986†  2008  India  ASCSulTmpSXTCip
DS  18 [I]  27 [S]    8 [S/S]  0.125 [S/S]  Phe464  ND  X1 
09-0350  2009  Unknown  Cip
DS  19 [I]  27 [S]    8 [S/S]  0.125 [S/S]  Phe464  Non-H58  X5 
09-2317  2009  French 
Guyana 
Pansusceptible  19 [I]  32 [S]    8 [S/S]  0.032 [S/S]  Glu468  Non-H58  X4 
*PFGE, pulsed-field gel electrophoresis; Nal, nalidixic acid; Cip, ciprofloxacin; ND, not determined; WT, wild type; A, ampicillin; S, streptomycin, C, 
chloramphenicol; Su, sulfamethoxazole; Tmp, trimethoprim; SXT, cotrimoxazole; Cip
DS, decreased susceptibility to ciprofloxacin. Disk diffusion test was 
performed and interpreted ([S], susceptible; [I], intermediate) following recommendations of antibiogram committee of the French Society for Microbiology 
(CA-SFM); MICs were determined by Etest strips and categorization was made according to CA-SFM and Clinical and Laboratory Standards Institute. 
†Previously described same patient (12).  
 
 
 
 
 
Figure 1. Scattergrams for 685 Salmonella enterica serotype Typhi isolates correlating the zone 
diameters around the 5-μg ciprofloxacin disk with those of the 30-μg nalidixic acid disk. Circle sizes are 
proportional to the number of isolates. Red lines indicate the respective antibiogram committee of the 
French Society for Microbiology (CA-SFM) breakpoints for ciprofloxacin (susceptible [S] >25; resistant [R] 
<22 mm). Blue lines indicate the respective CA-SFM breakpoints for nalidixic acid (S >20 and R <15 mm). Page 8 of 8 
 
Figure 2. XbaI pulsed-field gel electrophoresis (PFGE) profiles obtained from 10 Salmonella enterica 
serotype Typhi isolates belonging to subpopulation B. The dendrograms generated by BioNumerics 
version 3.5 software (Applied Maths, Sint-Martens-Latem, Belgium) show the results of cluster analysis 
on the basis of PFGE fingerprinting. Similarity analysis was performed by using the Dice coefficient, and 
clustering was done by using the unweighted pair-group method with arithmetic averages. 